Short report

Continuity and monitoring of antidepressant therapy in a primary care setting

David J Middleton BSc MB ChB
Foundation Year Doctor
Isobel M Cameron MA PhD
Lecturer
Ian C Reid PhD BMedBioL MBChB MRCPsych
Professor of Psychiatry
Applied Health Sciences (Mental Health), University of Aberdeen, Royal Cornhill Hospital, Aberdeen, Scotland, UK

ABSTRACT

Background Little is currently known about the continuity and monitoring of antidepressant treatment at individual patient level in primary care.
Aims To assess continuity of antidepressant therapy in a UK primary care setting at the individual patient level and whether this therapy is conducted with appropriate review.
Methods A systematic analysis was undertaken in two general practices in Aberdeen, Scotland of primary care records of adults initiated on an antidepressant for a new episode of depression or anxiety within a 12-month period and followed up for three years. Demographic and clinical details were recorded. Uni- and multivariate analyses were performed.
Results The sample consisted of 191 patients. Median duration of treatment for the first episode was 180 (inter-quartile range (IQR)=60, 429) days, with 29% of patients receiving an antidepressant for 60 days or less. Age and previous receipt of antidepressants contributed significantly to predicting treatment duration ($p<0.01$); effect size ($R^2=0.1$). The median interval between antidepressant review consultations increased progressively with increasing treatment duration. There were no significant predictors of frequency of antidepressant review.
Conclusion Depression management could be improved by assertive review (and better characterisation) of patients who discontinue early; and by scheduled reassessment of treatment in the second and subsequent years of continuation therapy.

Keywords: antidepressant, monitoring, primary care

How this fits in with quality in primary care?
What do we know?
Recently noted increases in duration of antidepressant prescribing in primary care are likely to reflect improved practice. However, little is currently known about the continuity and monitoring of antidepressant treatment at individual patient level.

What does this paper add?
A majority of patients may still receive treatment for an inappropriately short period, with younger and antidepressant naive patients being at greatest risk. Depression management could be improved by assertive review (and better characterisation) of patients who discontinue early; and by scheduled reassessment of treatment in the second and subsequent years of continuation therapy.
Introduction

The volume of antidepressant prescribing in the UK has increased substantially since the early 1990s, whilst the incidence and prevalence of depression has remained stable. This has largely been explained by an increase in the mean duration of treatment, rather than by inappropriate prescribing to individuals with subthreshold symptoms. It has previously been shown that antidepressant therapy is frequently prematurely discontinued, so these changes in prescribing patterns are likely to reflect improved adherence to current guidelines, which recommend continuation of treatment in all patients for at least six months after resolution of symptoms, and for at least two years in patients at high risk of recurrent depression. In addition, they recommend review of patients at two- to four-weekly intervals in the first three months after initiation of treatment, and at longer intervals thereafter. However, little is currently known about the continuity of antidepressant therapy in UK primary care at the level of individual patients, and whether this therapy is prescribed with appropriate review.

Methods

Two general practices within Aberdeen City, one urban (approximate patient list size 3500) and one suburban (approximate patient list size 10 500) participated. Each practice database was searched for prescriptions of antidepressants (selective serotonin reuptake inhibitors (SSRIs); selective norepinephrine reuptake inhibitors (SNRIs); or the other antidepressants – lofepramine, mianserin or trazodone) issued to adults (≥ 16 years old) for a new episode of depression or anxiety within the 12-month period following 1 April 2006. Antidepressants now more commonly prescribed for indications other than anxiety or depression (tricyclics) or those principally prescribed by specialists (monoamine-oxidase inhibitors) were not included. To ensure that all patients were being treated for a new episode, those who had received an antidepressant prescription in the six months prior to 1 April 2006 were excluded from the study population.

Data were collected from the initiation of antidepressant therapy for the following 1080 days (approximately three years), or until the end of therapy. An episode of antidepressant therapy was considered to have ended when a period greater than 60 days had elapsed from the end of the last prescription. The following data were collected from paper and electronic notes: demographics (including Scottish Index of Multiple Deprivation (SIMD) score); diagnosis; previous receipt of antidepressant prescriptions; significant co-morbidities (ischaemic heart disease, stroke, active cancer, chronic obstructive pulmonary disease, epilepsy, active thyroid dysfunction, chronic pain, rheumatoid arthritis or any other chronic seronegative arthropathy, fibromyalgia, systemic lupus erythematosus or inflammatory bowel disease); type, dose, dates and duration of antidepressant prescription; dates of consultations with a general practitioner (GP), and whether consultations included a review of antidepressant therapy. A GP consultation was designated as an ‘antidepressant review’ if any reference was made to mood, depression, anxiety or antidepressant therapy in the medical notes.

Data were analysed using SPSS Version 17. Continuous data were expressed as means (and standard deviation) or medians (and inter-quartile range (IQR)) as appropriate. All continuous data subject to univariate analysis were non-normal (except for age), so were assessed for significance using the Mann–Whitney U test and Spearman’s rank correlation. P-values were two-tailed. Variables associated with duration of treatment in the univariate analysis were entered into a stepwise multiple regression. Duration of treatment was log-transformed to allow normal distribution of residuals.

Results

The search of practice databases yielded 234 patients initiated on antidepressants within the reference period. Forty-four records were excluded due to: treatment occurring principally within secondary care (n = 7), antidepressants being prescribed for other indications (n = 35, e.g. insomnia, obsessive compulsive disorder, post-traumatic stress disorder, premenstrual tension) or notes being unavailable (n = 1). The remaining sample consisted of 191 patients. Descriptive statistics are presented in Table 1. One hundred and seventy-one (89.6%) patients initially received an SSRI, with three (1.6%) receiving an SNRI and 17 (8.9%) receiving other antidepressants. The median duration of treatment for the first episode was 180 (IQR = 60, 429) days, with 55 (28.8%) patients receiving antidepressants for 60 days or less. Ninety-five (49.7%) patients received an antidepressant for more than 180 days, with 53 (27.7%) on treatment for more than 360 days and 32 (16.8%) on treatment for more than 720 days. Among patients who had previously experienced three or more discrete episodes of antidepressant use (n = 34), the median duration of treatment was 269.5 (IQR = 144, 796) days, with 13 (38.2%) patients in treatment for more than 360 days and 10 (29.4%) in treatment for more than 720 days.
Age correlated with treatment duration (Spearman $r=0.27; p<0.01$). Significantly longer median treatment duration was observed among patients with comorbidities (median=242 days (IQR=113, 519) versus median=143 days (IQR=44, 339), $U=3388; p<0.05$), and among those who had received antidepressants previously (median=227 days (IQR=67, 858) versus median=128 days (IQR=30, 315), $U=3146.5, p<0.01$). Gender and SIMD score were not associated with treatment duration.

Age, presence of comorbidities and previous receipt of antidepressants were entered into the stepwise regression model. Only age and previous receipt of antidepressants contributed significantly ($p<0.01$), with a moderate effect size ($R^2=0.1$).9

Ninety-five patients completed more than 180 days of treatment. The median number of antidepressant review consultations (ARCs) for this period was three (IQR=2, 5) and the median number of GP consultations overall was four (IQR=3, 6). All but four patients had at least one ARC within 180 days of treatment initiation.

The median interval between ARCs increased progressively with increasing treatment duration (see Table 2), and by treatment day 900, 37.5% of patients who had remained in treatment for more than 540 days had experienced an interval of greater than 360 days between ARCs at some point during this time. There were no significant predictors of frequency of antidepressant review.

### Discussion

More than half of patients received a suboptimal duration of antidepressant therapy,8,10 and less than a third of those who had experienced three or more previous treatment episodes received two or more years of antidepressant therapy, in contrast to current guidelines.8

Thus, whilst the mean duration of antidepressant prescribing has increased,5 a substantial proportion of

#### Table 1 Demographic and clinical characteristics of study population ($n=191$)

<table>
<thead>
<tr>
<th>Demographic characteristics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Female (%)</td>
<td>136 (71.2)</td>
</tr>
<tr>
<td>Mean age (SD)$^a$</td>
<td>47.3 (15.8)</td>
</tr>
<tr>
<td>Median SIMD quintile (IQR)$^b$</td>
<td>3 (2–4)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Comorbidities (%)</td>
<td>71 (37.2)</td>
</tr>
<tr>
<td>Previously treated with antidepressants (%)</td>
<td>107 (56.0)</td>
</tr>
<tr>
<td>$\geq$3 previous episodes of antidepressant treatment (%)</td>
<td>34 (17.8)</td>
</tr>
</tbody>
</table>

$^a$ Standard deviation
$^b$ Inter-quartile range

#### Table 2 Frequency of antidepressant review consultations

<table>
<thead>
<tr>
<th>Treatment period</th>
<th>0–180 days</th>
<th>181–540 days</th>
<th>541–900 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>$N$</td>
<td>154</td>
<td>95</td>
<td>40</td>
</tr>
<tr>
<td>Interval between ARCs$^a$</td>
<td>37 (30–56)</td>
<td>72 (40–120)</td>
<td>120 (48–180)</td>
</tr>
<tr>
<td>% not attending an ARC for $&gt;360$ days</td>
<td>–</td>
<td>6.1%</td>
<td>37.5%</td>
</tr>
</tbody>
</table>

$^a$ Antidepressant review consultations
patients may still be prematurely discontinuing treatment, suggesting that a further increase in mean treatment duration would be desirable. Possible explanations for this include inadequate explanation to patients of the importance of continuing treatment in relapse prevention or patients’ preference to be antidepressant-free (due to side effects or stigma). Duration of treatment being positively associated with age concurs with other findings.11

Patients in our study were reviewed more frequently during the first 180 days of antidepressant therapy than at any other time in their treatment. The vast majority (85%) attended at least three ARCs within this period, indicating that most received appropriate monitoring during this phase. Patients not reviewed during this period had a history of previous antidepressant treatment; this may be a risk factor for inadequate review in the acute phase of treatment.

The decrease in frequency of antidepressant monitoring with longer treatment duration corresponds with increasing distance from the acute phase and patients’ greater familiarity with the treatment. Guidelines do not give clear recommendations for the frequency of review of antidepressant therapy after the acute treatment period.6,12 However, it is of concern that many of those who remain in treatment for over 540 days go on to experience an interval of more than 360 days between antidepressant reviews.

This was a small study that would benefit from replication in larger community samples. Some indicators of risk of recurrence (e.g. family history and severity of symptoms) were not reliably recorded so could not be investigated.

Conclusion

Despite recent increases in the average duration of antidepressant prescribing, a high proportion of patients in our study prematurely discontinued treatment. There is also evidence that some patients were not reviewed adequately during the second year of chronic treatment. Depression management could thus be improved by assertive review (and better characterisation) of patients who discontinue early; and by scheduled reassessment of treatment in the second and subsequent years of continuation therapy.

ACKNOWLEDGEMENTS

We would like to thank Ms Shraddha Agashe, Dr Graham Gould and Dr Richard Taylor for their invaluable assistance, and the staff at the practices who kindly participated.

REFERENCES


FUNDING

None. This work was conducted as DJM’s medical elective project.

ETHICAL APPROVAL

Ethical approval was not required for this study, which was primarily undertaken to audit appropriateness of prescribing and monitoring in the practices.
PEER REVIEW
Not commissioned; externally peer reviewed.

CONFLICTS OF INTEREST
DJM, IMC and ICR have no conflicts of interest to declare. IMC and ICR conceived the original idea. All authors designed the study. DJM collected the data, DJM and IMC analysed the data and DJM wrote the initial draft. All authors critically revised the manuscript and approved the final version.

ADDRESS FOR CORRESPONDENCE
Dr Isobel M Cameron, Applied Clinical Sciences (Mental Health), University of Aberdeen, Royal Cornhill Hospital, Aberdeen AB25 2ZH, Scotland, UK. Tel: +44 (0)1224 557971; fax: +44 (0)1224 557400; email: i.m.cameron@abdn.ac.uk

Received 6 October 2010
Accepted 6 February 2011